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Background: Cervical cancer poses a huge health burden, both to developed and developing nations, making
prevention and control strategies necessary. However, the challenges of designing and implementing prevention
strategies differ for low- and middle-income countries (LMICs) as compared to countries with fully developed
health care systems. Moreover, for many LMICs, much of the data needed for decision analytic modelling, such as
prevalence, will most likely only be partly available or measured with much larger uncertainty. Lastly, imperfect
implementation of human papillomavirus (HPV) vaccination may influence the effectiveness of cervical cancer
prevention in unpredictable ways. This systematic review aims to assess how decision analytic modelling studies
of HPV cost-effectiveness in LMICs accounted for the particular challenges faced in such countries. Specifically, the
study will assess the following: (1) whether the existing literature on cost-effectiveness modelling of HPV vaccines
acknowledges the distinct challenges of LMICs, (2) how these challenges were accommodated in the models,
(3) whether certain parameters systemically exhibited large degrees of uncertainty due to lack of data and how
influential were these parameters on model-based recommendations, and (4) whether the choice of modelling
herd immunity influences model-based recommendations, especially when coverage of a HPV vaccination program
is not optimal.
Methods: We will conduct a systematic review to identify suitable studies from MEDLINE (via PubMed), EMBASE,
NHS Economic Evaluation Database (NHS EED), EconLit, Web of Science, and CEA Registry. Searches will be
conducted for studies of interest published since 2006. The searches will be supplemented by hand searching
of the most relevant papers found in the search. Studies will be critically appraised using Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) statement checklist. We will undertake a descriptive, narrative,
and interpretative synthesis of data to address the study objectives.
Discussion: The proposed systematic review will assess how the cost-effectiveness studies of HPV vaccines
accounted for the distinct challenges of LMICs. The gaps identified will expose areas for additional research as well
as challenges that need to be accounted for in future modelling studies.
Systematic review registration: PROSPERO CRD42015017870.
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Cervical cancer poses one of the greatest challenges to
women’s health. It is estimated that over a million
women worldwide currently have cervical cancer, most
of whom have not been diagnosed nor have access to
treatment that could cure them or extend their survival
[1]. The burden of cervical cancer is disproportionately
borne by poorer countries. In 2012, 528,000 new cases
of cervical cancer were diagnosed, and 266,000 women
died of the disease, nearly 90 % of them in low- and
middle-income countries (LMICs) [1]. It is expected that
these numbers will double in the next 20 years due to
aging and population growth [2].
The human papillomavirus (HPV) is the primary cause
of cervical cancer and cervical intraepithelial neoplasia
(CIN) [3]. HPV is typically transmitted in the cervix
through microabrasions that may occur as a result of
sexual intercourse [4]. Persistent infection with onco-
genic strains of HPV causes cervical cancer [5]. Of the
40 HPV strains that affect the genital area, 15 of them
are known to be oncogenic (types 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 68, 73, and 82) [6]. HPV infection
has also been linked with other genital cancers (e.g., va-
ginal, vulvar, anal, and penile) as well as non-life-
threatening diseases, such as genital warts [7]. HPV
types 16 and 18 have been found to be responsible for
about 70 % of all cervical cancer cases worldwide [8, 9].
In the remaining 30 % of cervical cancers, HPV types 31,
33, 35, 45, and 58 have all been implicated [10].
Cervical cancer can be prevented both by primary pre-
vention through HPV vaccination and by secondary pre-
vention through cervical cancer screening. Conventional
cytology-based screening, combined with colposcopy
and treatment of precursor lesions, has been the gold
standard for the secondary prevention of cervical cancer.
It has greatly reduced cervical cancer incidence and
mortality from cervical cancer in many developed coun-
tries. Cytology-based screening is not as widespread in
developing countries [10]. For instance, it is estimated
that less than 5 % of women at risk of cervical cancer in
sub-Saharan Africa have ever been screened [11].
Alternatives to cytology-based screening include visual
inspection with acetic acid (VIA) and newer molecular
testing for infection of the cervix with high-risk types of
HPV DNA. VIA and HPV DNA testing have proven to
be effective screening methods [12, 13]. HPV DNA test-
ing has shown to be significantly more effective than
VIA or cytology in reducing both cervical cancer precur-
sors and cervical cancer [12, 13].
There currently are two HPV vaccines in widespread use.
Both Cervarix® and Gardasil® offer protection against HPV
16 and 18, respectively, the two most oncogenic types [7].
Gardasil® also offers protection against HPV 6 and 11,
which cause 90 % of genital warts [14]. The quadrivalentvaccine has also shown to protect against cancers of the
anus, vagina, and vulva [14]. There is evidence indicating
that the immune response against type 16 and 18 provides
some cross-protection against types 45 and 31, both im-
portant in the aetiology of cervical cancer, thus potentially
increasing the projected protection from vaccination to
75–80 % [10]. However, since prophylactic vaccination is
not effective against infection from all 15 oncogenic HPV
types, regular screening is still recommended among
women that have received the vaccination [14].
Challenges of prevention and control strategies in
low- and middle-income countries
The World Health Organization’s (WHO) recommendation
for comprehensive cervical cancer prevention and control
strategy includes primary, secondary, and tertiary preven-
tion activities [1]. Primary prevention involves HPV vaccin-
ation of girls (and boys if affordable) between 9 to 13 years.
In secondary prevention, women 30 years of age or older
are to be “screened-and-treated” with low-cost technology,
e.g., VIA followed by cryotherapy or HPV testing for high-
risk HPV type. For tertiary prevention, all women with in-
vasive cancer at any age are to be treated with ablative sur-
gery, radiotherapy, or chemotherapy with palliative care as
necessary. The recommendation suggests that the three
prevention components be planned and implemented in
combination with a structured national approach to com-
munity education and mobilization strategies and a national
monitoring and evaluation system [1].
LMICs potentially face a number of challenges in imple-
menting such a cervical cancer prevention and control
program. Existing health services may not have the cap-
acity to accommodate additional interventions, and thus,
extra cost will be incurred to set up such a program. Re-
source constraints may necessitate implementation of a
program in phases rather than immediate implementation.
Resource constraints could also require the introduction
of preventive and treatment services only for certain re-
gions rather than country-wide. Sections of the population
may systematically avoid participation in such a program.
Given these potential challenges, it is therefore important
to examine if and how they are accounted for by decision
analytic models of HPV vaccines; for example, do analyses
adopt a different modelling structure or just change pa-
rameters for the constraints mentioned above?
Data challenges in low- and middle-income countries
The data needed for modelling might be less readily avail-
able in LMICs or measured with much larger uncertainty.
HPV-related outcome data in many LMICs may have poor
resolution and are also often highly aggregated [15]. For ex-
ample, incidence data of cervical cancer available from the
WHO/Institut Català d’Oncologia Information Center on
HPV and Cervical Cancer is stratified into the age groups
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simple natural history models may erroneously predict that
15-year-old women have the same cancer incidence as 44-
year-old women, and this overestimates the proportion of
cancers occurring in younger women and thus potentially
biases estimates of vaccination cost-effectiveness [15].
These data challenges prompt the questions of how well
they are recognized and overcome by the existing literature
and which of these uncertain parameters have the greatest
impact on the model outcomes. These are pertinent ques-
tions, and it is worthwhile examining how they have been
handled in modelling studies of HPV vaccination.
Model type and herd immunity
There are three types of models that have been employed
in cost-effectiveness analyses of HPV vaccination: static
models, transmission dynamic models, and hybrid models
combining features of both static and dynamic models [7].
A static model typically tracks progression of HPV disease
for a single cohort over an expected lifetime [16]. Trans-
mission dynamic models have the advantage of accounting
for both the direct and indirect (i.e., herd immunity) bene-
fits of vaccination in the population [16]. Thus, dynamic
models account for the immunity that occurs when HPV
vaccination of a significant portion of the population (or
herd) provides a measure of protection for individuals
who have not been vaccinated. A hybrid model is a com-
bination of a cohort model and a dynamic model. It cor-
rects the invariant incidence probability in a cohort model
to a dynamic probability and thus does not ignore the in-
direct benefits of herd immunity for the cohort being sim-
ulated [16]. However, herd immunity depends on the rate
of vaccine coverage. As stated previously, this coverage
may vary dramatically in LMICs, both across time or
across populations. It is therefore relevant to ask how this
is accounted for in HPV vaccine cost-effectiveness studies.
Study rationale and objectives
Appraising the introduction of HPV vaccines requires
estimation of the avertable disease burden, cost-
effectiveness of the vaccine compared with alternative
uses of the resources, affordability of the vaccine, feasi-
bility of achieving high coverage, likelihood of public ac-
ceptability, and political support for vaccination [17].
The lack of data on the long-term effectiveness of HPV
vaccination has prompted the development of various
decision analytic models to guide policy makers by pro-
jecting the long-term epidemiologic and economic con-
sequences of alternative vaccination policies [16]. For
such analyses to provide a reliable guide to policy devel-
opment and implementation, they should reflect the
LMIC-specific challenges described above.
Two systematic reviews of cost-effectiveness analyses of
HPV vaccination in LMICs have been published previously[18, 19]. These reviews discussed the cost-effectiveness es-
timates and investigated how they are affected by model
characteristics and underlying assumptions in general. The
focus of our proposed systematic review is to examine how
the modelling studies accounted for the challenges specific
to low- and middle-income countries. The review seeks to
answer the following questions:
 Does the existing literature on cost-effectiveness
modelling of HPV vaccine acknowledge the
particular challenges facing LMICs?
 How were particular challenges accommodated in
the models, e.g., through a different model structure
or just by varying parameters?
 Is the uncertainty among the less readily available
essential data/parameters regarding LMICs so large
that the model-based recommendation is affected?
 Does the choice of modelling herd immunity
influence model-based recommendations, and in




This protocol adheres to the Preferred Reporting Items in
Systematic Reviews and Meta-analyses (PRISMA) state-
ment [20]. The protocol is registered in the International
Prospective Register of Systematic Reviews (PROSPERO)
CRD42015017870.
Eligibility criteria
Inclusion criteria are as follows:
 Studies based on decision analytical models of HPV
vaccination;
 Studies that considered the cost-effectiveness of
HPV vaccination and reported the additional cost
and additional health effects in terms of life years
gained (LYGs), quality-adjusted life years (QALYs),
or disability-adjusted life year (DALYs);
 LMICs as identified by the World Bank classification
of income groups [21];
 Both single- and multi-country studies;
 The review will include both original research
papers and reviews (inclusion of the latter is to
ensure that no original study was missed);
 Studies to be included in the review could be
published in any language;
 Studies published since 2006.
Information sources
We will search MEDLINE (via PubMed), EMBASE, NHS
Economic Evaluation Database (NHS EED), EconLit, Web
of Science, and Tufts CEA Registry. For existing systematic
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base of Abstracts of Reviews of Effects (DARE), and
Cochrane Health Technology Assessment Databases. Re-
views will be included to reduce the possibility of missing
an individual study.
Search strategy
A search strategy will be developed for each of the data-
bases. The “Appendix” section provides details of our
planned bibliographic database search strategies for
MEDLINE (via PubMed), EMBASE, CINAHL, Cochrane
Reviews/Cochrane DARE/NHS EED, EconLit, Web of
Science, and CEA Registry. The reference lists of all in-
cluded and relevant articles identified during the search
will be reviewed to identify further studies that were
missed. Furthermore, we will use the PubMed “related
articles” feature. Hand searching of a selection of rele-
vant journals will be conducted as advised by experts in
economic evaluation.
Study selection
Titles and abstracts will be screened for inclusion inde-
pendently by two of the reviewers using the eligibility
criteria. Opinion of a third reviewer will be sought to ar-
rive at a consensus in case of disagreement on a study
for inclusion.
Data extraction
Data will be extracted independently by two of the re-
viewers from included studies using a predefined data
extraction spreadsheet (Table 1). Data to be extracted
will be arranged into the following classes: model char-
acteristics, base-case assumptions, results, sensitivity/un-
certainty analyses, data sources, and miscellaneous
(conflict of interests and factors not considered). Cost
presented in different currencies will be adjusted to 2013
value using consumer price index. Afterwards, cost data
will be converted to international dollar units using pur-
chasing power parities (PPPs). Authors of various studies
may be contacted to clarify methods and results if the
need arises.
Risk of bias and data synthesis
One of the investigators will assess the validity of in-
cluded studies using the Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) statement
[22]. Details of the CHEERS statement are summarized
in Table 2. Descriptive, narrative, and interpretative syn-
thesis of data will be undertaken to address the study
objectives [23]. The WHO Commission on Macroeco-
nomics and Health will be used to determine the thresh-
olds of cost-effectiveness such that an intervention will
be considered “very cost effective” and “cost effective”
when its incremental cost-effectiveness ratio is less thanthe gross domestic product (GDP) per capita and less
than three times GDP per capita, respectively [23].
Discussion
This protocol describes a systematic review for studies
on cost-effectiveness of prophylactic HPV vaccination in
LMICs. The aim is to assess how cost-effectiveness stud-
ies of HPV vaccine accounted for the individual chal-
lenges of low- and middle-income countries. The gaps
identified in this systematic review will expose areas for
additional research as well as challenges that need to be
accounted for in future modelling studies. The review
will also present current data on cost-effectiveness of
HPV vaccines in LMICs as newer studies have been car-
ried out since the publication of the last reviews.
Appendix: Details of electronic bibliographic
database search strategies
MEDLINE (via PubMed)
(“Human papillomavirus 6” [mesh] OR “Human papilloma-
virus 16” [mesh] OR “Human papillomavirus 18” [mesh]
OR “Human papillomavirus 31” [mesh] OR Alphapapillo-
mavirus [mesh] OR Papillomavirus* [tiab] OR human papil-
loma* [tiab] OR HPV [tiab] OR “Papillomavirus Infections”
[mesh] OR Papillomaviridae [mesh] OR Papillomavirid*
[tiab] OR Uterine Cervical Neoplasms [mesh] OR cervix
cancer* [tiab] OR cervix carcinom* [tiab] OR cervix malig-
nan* [tiab] OR cervix neoplas* [tiab] OR cervix tumor*
[tiab] OR cervical cancer* [tiab] OR cervical carcinom*
[tiab] OR cervical malignan* [tiab] OR cervical neoplas*
[tiab] OR cervical tumor* [tiab] OR Cervical Intraepithelial
Neoplasia [mesh] OR Cervical Intraepithelial Neoplasia
[tiab] OR CIN [tiab])
AND
(Vaccination [mesh] OR mass vaccination [mesh] OR
Papillomavirus Vaccines [mesh] OR vaccin* [tiab] OR
immunization [mesh] OR Immunization Programs [mesh]
OR immuni* [tiab] OR “human papillomavirus vaccine
L1, type 6,11,16,18” [Supplementary Concept] OR “human
papillomavirus vaccine, L1 type 16, 18” [Supplementary




(Economics [mesh] OR Quality of Life [mesh:NoExp]
OR Value of Life [mesh:NoExp] OR Quality-Adjusted
Life Years [mesh:NoExp] OR Models, Economic [mesh:-
NoExp] OR Markov Chains [mesh:NoExp] OR Monte
Carlo Method [mesh:NoExp] OR Decision trees [mesh:-
NoExp] OR economic* [tiab] OR cost* [tiab] OR cost-
ing* [tiab] OR costly [tiab] OR costed [tiab] OR price*
[tiab] OR pricing* [tiab] OR pharmacoeconomic* [tiab]
OR pharmaco-economic* [tiab] OR budget* [tiab] OR
expenditure* [tiab] OR (value [tiab] AND (money [tiab]
Table 1 Relevant data extraction information
Data extraction category Specific information to extract
A. Model characteristics
Model Author(s), year of publication, model design (static model, dynamic model,
or hybrid model)
Perspective Providers, patients, or societal perspective
Benefits (QALY, DALY, YLS) Measured in quality-adjusted life years (QALYs), disability-adjusted life years
(DALY), years of life saved (YLS)
B. Base-case assumptions
Current routine practice efficacy Efficacy of the current screening practice (cytology-based screening, DNA
screening, or visual inspection with acetic acid) used as the comparator
Screening age/screening interval Age at which women commence screening and screening interval
Vaccine coverage in target groups Current HPV vaccination coverage
Age for vaccination Age group eligible to receive HPV vaccination
Estimated effective coverage HPV vaccination coverage and the rationale for the assumption
Screening compliance Estimate used for comparison with current practice
Sensitivity/specificity of the screening Sensitivity/specificity estimate for the screening methods
Duration of vaccine protection Total length of time HPV vaccination is assumed to protect the recipient
from acquiring infection
Cost of vaccine per three doses (and booster if included) Market cost or subsidized cost. Other cost associated with vaccination, e.g.,
freight, storage, and program cost. School-based-delivery cost or
health-facility-based delivery cost
Discounting rate Discounting rate used to adjust for time preference for money
C. Results
Incremental cost-effectiveness ratio (ICER) The most cost-effective protocol compared with the second best protocol
Year based for currency value The year which the analysis was conducted
Adjusted ICER (to 2014) Adjusted ICER to reflect 2014 value
Data sources
Source(s) Data source used to derive estimates of HPV-related epidemiologic outcomes,
e.g., HPV (type-specific) prevalence, cervical cancer incidence, probability of
HPV transmission given a sexual partnership, and crude mortality from
cervical cancer.
D. Sensitivity and uncertainty
Sensitivity analysis Parameters that had the highest effect on model-based recommendation.
Uncertainty analysis The contribution of individual parameters on overall uncertainty (when reported).
E. Miscellaneous
Funding and conflict of interest Funding for the study and the role of the funder in the study. Possible conflict
of interest declared by the author
Factors not taken into account How did model acknowledge and account for special challenges of the LMIC?
Choice of modelling herd immunity
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quality of life [tiab] OR qol* [tiab] OR hrqol* [tiab] OR
quality adjusted life year* [tiab] OR qaly* [tiab] OR cba
[tiab] OR cea [tiab] OR cua [tiab] OR utilit* [tiab] OR
markov* [tiab] OR monte carlo [tiab] OR (decision [tiab]
AND (tree* [tiab] OR analys* [tiab] OR model* [tiab]))
OR ((clinical [tiab] OR critical [tiab] OR patient [tiab])
AND (path* [tiab] OR pathway* [tiab])) OR (managed
[tiab] AND (care [tiab] OR network* [tiab])))(just) EMBASE
(‘Human papillomavirus type 6’/exp OR ‘Human papillo-
mavirus type 16’/exp OR ‘Human papillomavirus type
18’/exp OR ‘Human papillomavirus type 31’/exp OR
‘Alphapapillomavirus’/exp OR ‘Papillomavirus Infection’/
exp OR ‘Papilloma virus’/exp OR ‘uterine cervix cancer’/
exp OR (Papillomavirus* OR human papilloma* OR
HPV OR Papillomavirid*):ab,ti OR ((cervix OR cervical)
NEAR/3 (cancer* OR carcinoma* OR malignanc* OR
Table 2 CHEERS statement for checking the validity of included studies [22]
Selection/item Item no. Recommendation
Title and abstract
Title 1 Identify the study as an economic evaluation, or use more specific
terms such as “cost-effectiveness analysis” and describe the
interventions compared.
Abstract 2 Provide a structured summary of objectives, perspective, setting,
methods (including study design and inputs), results (including
base-case and uncertainty analyses), and conclusions.
Introduction
Background and objectives 3 Provide an explicit statement of the broader context for the study.
Present the study question and its relevance for health policy or
practice decisions.
Methods
Target population and subgroups 4 Describe characteristics of the base-case population and subgroups
analyzed including why they were chosen.
Setting and location 5 State relevant aspects of the system(s) in which the decision(s)
need(s) to be made.
Study perspective 6 Describe the perspective of the study and relate this to the costs
being evaluated.
Comparators 7 Describe the interventions or strategies being compared and state
why they were chosen.
Time horizon 8 State the time horizon(s) over which costs and consequences are
being evaluated and say why appropriate.
Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes
and say why appropriate.
Choice of health outcomes 10 Describe what outcomes were used as the measure(s) of benefit in
the evaluation and their relevance for the type of analysis performed.
Measurement of effectiveness 11a Single study-based estimates: describe fully the design features of the
single effectiveness study and why the single study was a sufficient
source of clinical effectiveness data.
11b Synthesis-based estimates: describe fully the methods used for the
identification of included studies and synthesis of clinical
effectiveness data.
Measurement and valuation of preference-based outcomes 12 If applicable, describe the population and methods used to elicit
preference outcomes.
Estimating resources and costs 13a Single study-based economic evaluation: describe approaches used to
estimate resource use associated with the alternative interventions.
Describe primary or secondary research methods for valuing each
resource item in terms of its unit cost. Describe any adjustments
made to approximate to opportunity costs.
13b Model-based economic evaluation: describe approaches and data
sources used to estimate resource use associated with model health
states. Describe primary or secondary research methods for valuing
each resource item in terms of its unit cost. Describe any adjustments
made to approximate to opportunity costs.
Currency, price date, and conversion 14 Report the dates of the estimated resource quantities and unit costs.
Describe methods for adjusting estimated unit costs to the year of
reported costs if necessary. Describe methods for converting costs
into a common currency base and the exchange rate.
Choice of mode 15 Describe and give reasons for the specific type of decision analytic
model used. Providing a figure to show model structure is
strongly recommended.
Assumptions 16 Describe all structural or other assumptions underpinning the decision
analytic model.
Ekwunife et al. Systematic Reviews  (2015) 4:68 Page 6 of 9
Table 2 CHEERS statement for checking the validity of included studies [22] (Continued)
Analytic methods 17 Describe all analytic methods supporting the evaluation. This could
include methods for dealing with skewed, missing, or censored data;
extrapolation methods; methods for pooling data; approaches to
validate or make adjustments (e.g., half-cycle corrections) to a model;
and methods for handling population heterogeneity and uncertainty.
Results
Study parameters 18 Report the values, ranges, references, and, if used, probability distributions
for all parameters. Report reasons or sources for distributions used to
represent uncertainty where appropriate. Providing a table to show the
input values is strongly recommended.
Incremental costs and outcomes 19 For each intervention, report mean values for the main categories of
estimated costs and outcomes of interest, as well as mean differences
between the comparator groups. If applicable, report incremental
cost-effectiveness ratios.
Characterizing uncertainty 20a Single study-based economic evaluation: describe the effects of sampling
uncertainty for estimated incremental cost, incremental effectiveness,
and incremental cost-effectiveness, together with the impact of
methodological assumptions (such as discount rate, study perspective).
20b Model-based economic evaluation: describe the effects on the results of
uncertainty for all input parameters and uncertainty related to the
structure of the model and assumptions
Discussion
Study findings, limitations, generalizability,
and current knowledge
22 Summarize key study findings and describe how they support the
conclusion reached. Discuss limitation and the generalizability of the
findings and how the findings fit with current knowledge.
Others
Source of funding 23 Describe how the study was funded and the role of the funder in the
identification, design, conduct, and reporting of the analysis. Describe
other non-monetary sources of support.
Conflicts of interest 24 Describe any potential for conflict of interest among study contributors
in accordance with journal policy. In the absence of a journal policy, we
recommend authors comply with International Committee of Medical
Journal Editors’ recommendations.
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oma in situ’/exp OR (“Cervical Intraepithelial Neoplasia”
OR CIN):ab,ti)
AND
(‘Immunization’/exp OR ‘Cancer immunization’/exp
OR ‘mass immunization’/exp OR ‘Vaccination’/exp OR
‘Wart virus vaccine’/exp OR (vaccin* OR immuni* OR





(‘health economics’/exp OR ‘health care cost’/exp OR
‘quality of life’/exp OR ‘quality adjusted life year’/exp
OR ‘Monte Carlo method’/exp OR ‘decision tree’/exp
OR (economic* OR cost* OR costing* OR costly OR
costed OR price* OR pricing* OR pharmacoeconomic*
OR budget* OR expenditure* OR fee OR fees OR ‘qual-
ity of life’ OR qol* OR hrqol* OR qaly* OR CBA OR
CEA OR CUA OR utilit* OR markov*):ab,ti OR (phar-
maco NEXT/1 economic*):ab,ti OR (value NEAR/1
(money OR monetary)):ab,ti OR (‘quality adjusted life’NEXT/1 year*):ab,ti OR (monte NEXT/1 carlo):ab,ti OR
(decision NEXT/3 (tree* OR analys* OR model*)):ab,ti
OR ((clinical OR critical OR patient) NEXT/1 (path*
OR pathway*)):ab,ti OR (managed NEXT/3 (care OR
network*)):ab,ti)
EconLit and CINAHL (via EBSCO)
MH Papilloma OR MH Papillomaviruses OR MH “papil-
lomavirus infections” OR AB (papilloma OR papilloma-
virus* OR HPV) OR MH “cervix neoplasms” OR MH
“uterine neoplasms” OR AB ((cancer* OR carcinoma*
OR malignanc* OR neoplasm* OR tumor*) N3 (uterine
OR cervix OR cervical)) OR MH “Cervical Intraepithe-
lial Neoplasia” OR AB CIN AND MH “papillomavirus
vaccine” OR MH immunization OR MH “Immunization
Programs” OR AB (immuni?ation OR vaccin* OR garda-
sil OR cervarix) AND PD (2006 OR 2007 OR 2008 OR
2009 OR 201*) AND MH Health Resource Allocation
OR MH Health Care Delivery OR MH Health Care
Costs OR MH Economic Value of Life OR MH Quality
of Life OR MH Quality-Adjusted Life Years OR MH De-
cision Trees OR AB (economic* OR cost* OR costing*
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coeconomic* OR budget* OR expenditure* OR fee OR
fees OR “quality of life” OR qol* OR hrqol* OR qaly* OR
CBA OR CEA OR CUA OR utilit* OR markov*) OR AB
((pharmaco N1 economic*) OR (value N1 (money OR
monetary)) OR (“quality adjusted life” N1 year*) OR
(monte N1 carlo) OR (decision N3 (tree* OR analys*
OR model*)) OR ((clinical OR critical OR patient) N1 (path*
OR pathway*)) OR (managed N3 (care OR network*)))
Cochrane Reviews/Cochrane DARE/NHS EED/HTA database
MeSH descriptor: [Human papillomavirus 6] explode all
trees OR MeSH descriptor: [Human papillomavirus 16]
explode all trees OR MeSH descriptor: [Human papillo-
mavirus 18] explode all trees OR MeSH descriptor: [Hu-
man papillomavirus 31] explode all trees OR MeSH
descriptor: [Alphapapillomavirus] explode all trees OR
MeSH descriptor: [Papillomaviridae] explode all trees
OR MeSH descriptor: [Papillomavirus Infections] ex-
plode all trees OR MeSH descriptor: [Uterine Cervical
Neoplasms] explode all trees OR MeSH descriptor:
[Uterine Neoplasms] explode all trees OR MeSH de-
scriptor: [Cervical Intraepithelial Neoplasia] explode all
trees OR (Papillomavirus* OR human papilloma* OR
HPV OR Papillomavirid* OR ((cervix OR cervical)
NEAR/3 (cancer* OR carcinoma* OR malignanc* OR
neoplasm* OR tumor*)) OR “Cervical Intraepithelial
Neoplasia” OR CIN):ti,ab,kw
AND
MeSH descriptor: [Papillomavirus Vaccines] explode
all trees OR MeSH descriptor: [Immunization] explode
all trees OR MeSH descriptor: [Vaccination] explode all
trees OR MeSH descriptor: [Mass Vaccination] explode
all trees OR MeSH descriptor: [Immunization Programs]
explode all trees OR (vaccin* OR immuni* OR Gardasil
OR Cervarix):ti,ab,kw
AND
MeSH descriptor: [Economics] explode all trees OR
MeSH descriptor: [Economics, Medical] explode all trees
OR MeSH descriptor: [Economics, Pharmaceutical] ex-
plode all trees OR MeSH descriptor: [Health Care Eco-
nomics and Organizations] explode all trees OR MeSH
descriptor: [Health Care Costs] explode all trees OR
MeSH descriptor: [quality of life] explode all trees
OR MeSH descriptor: [value of life] explode all trees OR
MeSH descriptor: [Quality-Adjusted Life Years] explode
all trees OR MeSH descriptor: [Markov Chains] explode
all trees OR MeSH descriptor: [Monte Carlo method]
explode all trees OR MeSH descriptor: [decision trees]
explode all trees OR (economic* OR cost* OR costing*
OR costly OR costed OR price* OR pricing* OR phar-
macoeconomic* OR budget* OR expenditure* OR fee
OR fees OR ‘quality of life’ OR qol* OR hrqol* OR qaly*
OR CBA OR CEA OR CUA OR utilit* OR markov* OR(pharmaco NEXT/1 economic*) OR (value NEAR/1
(money OR monetary)) OR (‘quality adjusted life’
NEXT/1 year*) OR (monte NEXT/1 carlo) OR (decision
NEXT/3 (tree* OR analys* OR model*)) OR ((clinical
OR critical OR patient) NEXT/1 (path* OR pathway*))
OR (managed NEXT/3 (care OR network*))):ti,ab,kw
AND
Limit Publication Date: 01-1-2006 till now
Web of Science (Core Collection)
TS = (((cervix OR cervical) NEAR/3 (cancer* OR carcin-
oma* OR malignanc* OR neoplasm* OR tumor*)) OR
Papillomavirus* OR human papilloma* OR HPV OR
Papillomavirid* OR “Cervical Intraepithelial Neoplasia”
OR CIN)
AND
TS = (vaccin* OR immuni* OR Gardasil OR Cervarix)
AND
PY = (2006–2015) AND TS = (health econom* OR
health care cost* OR Monte Carlo OR economic* OR
cost* OR costing* OR costly OR costed OR pri?e* OR
pri?ing* OR pharmacoeconomic* OR pharmaco eco-
nomic* OR budget* OR expenditure* OR fee OR fees
OR quality of life OR quality adjusted life year* OR qol*
OR hrqol* OR qaly* OR CBA OR CEA OR CUA OR uti-
lit* OR markov* OR (value NEAR/1 (money OR monet-
ary OR life)) OR (decision NEXT/3 (tree* OR analys*
OR model*)) OR ((clinical OR critical OR patient)
NEAR/1 (path* OR pathway*)) OR (managed NEAR/3
(care OR network*)))
CEA Registry
Basic/manual search by the following keywords (pub-
lished 2006–2015): Papilloma, Papillomavirus, Papillo-
maviridae, HPV 74, cervix, cervical, uterine, Gardasil
and Cervari
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